Oral zervimesine reduced GA lesion growth in phase 2 study from Cognition Therapeutics

Published on May 8, 2025
Topline results from the Magnify phase 2 clinical trial of oral zervimesine show 28.6% slower geographic atrophy lesion growth compared with placebo.
Continue reading on website
Other news

Boehringer Ingelheim kicks off dual phase 2 clinical studies for geographic atrophy candidates

May 8, 2025
Boehringer Ingelheim announced that the phase 2 clinical studies will investigate a potential first-in-class oral compound and a highly specific antibody fragment for geographic atrophy.

CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease

May 8, 2025
Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda light delivery system (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.